There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Background: Bone metastases are a common cause of morbidity in patients with prostate
carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone …

In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion
every 3 weeks for 15 months) reduced the incidence of skeletal-related events (SREs) in …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

BACKGROUND PD‐L1 (programmed death ligand 1, B7‐H1) is a cell surface glycoprotein
that can impair T‐cell function. PD‐L1 is aberrantly expressed by multiple human …

Background Treatment of localised renal cell carcinoma consists of partial or radical
nephrectomy. A substantial proportion of patients are at risk for recurrence because no effective …

The cancer transcriptome is remarkably complex, including low-abundance transcripts, many
not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we …

Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate data obtained
from a large, multi‐institutional, contemporary series of patients who underwent radical …

The p27 Kip1 gene codes for a cyclin-dependent kinase inhibitor implicated in G 1 arrest by
transforming growth factor β, cell-cell contact, agents that elevate cyclic AMP, and the growth-…

Growing evidence suggests that tumor-associated macrophages (TAM) promote cancer
progression and therapeutic resistance by enhancing angiogenesis, matrix-remodeling, and …